接受全身治疗的原发性妇科癌症患者的性健康与性功能
本研究前瞻性纳入100例接受全身治疗的妇科癌症患者,97例完成调查。复发治疗组76%和初始治疗组75%近一月无性活动(p=1.0),67%希望未来有性活动;完成FSFI的31例中位评分24.0,68%存在性功能障碍。
要点
- 多数接受全身治疗的妇科癌症患者存在性功能障碍且当前无性活动。
- 复发治疗组阴道干燥更常见(p=0.09),初始治疗组因健康问题无性活动更常见(p=0.07)。
- 67%患者希望未来有性活动,多数愿意讨论性功能问题。
核心结论
- 许多接受全身治疗的妇科癌症患者愿意讨论性功能,多数报告性功能障碍且当前无性活动,理解患者的性功能困扰有助于提供者进行干预。
研究设计与样本
- 前瞻性研究,纳入18岁及以上接受初始或复发全身治疗的妇科癌症女性,排除接受放疗者,共97例完成调查。
主要发现
- 145例中100例(69%)入组,97例(67%)完成调查,中位年龄65岁,卵巢癌58%、子宫内膜癌34%、宫颈癌8%。
- 复发治疗组52例(54%),初始治疗组45例(46%)。
- 复发组38例(76%)与初始组34例(75%)近一月无性活动(p=1.0),61例(67%)报告希望未来有性活动。
- 完成全部FSFI问题的31例中位FSFI评分为24.0,21例(68%)存在性功能障碍。
- 复发治疗组阴道干燥更常见(p=0.09),初始治疗组因「健康状况」无性活动更常见(p=0.07)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sexual dysfunction has been reported after gynecologic cancer treatment but few studies have examined sexual function during treatment. Our objectives were to describe sexual function among women receiving systemic therapy for gynecologic cancers and to compare sexual function between women receiving upfront treatment versus treatment for cancer recurrence. METHODS: We conducted a prospective study of women 18yo and older receiving systemic therapy for gynecologic cancer in the upfront or recurrent setting. Patients receiving radiation were excluded. Participants completed a survey with questions from the Patient Reported Outcome Measurement Information System (PROMIS) SexFS and Female Sexual Function Index (FSFI). Clinical information was collected from chart review. Statistical analysis included t-test, Wilcoxon rank sum test, and Fisher's exact test. RESULTS: Of 145 patients approached, 100 (69%) enrolled and 97 (67%) completed the survey. Median age was 65yo. Most patients had ovarian cancer (58%), then endometrial cancer (34%) and cervical cancer (8%). Fifty-two (54%) were receiving recurrent treatment and 45 (46%) upfront treatment. Thirty-eight (76%) in the recurrent group and 34 (75%) in the upfront group hadn't been sexually active in the last month (p = 1.0); however, 61 (67%) participants reported a desire for future sexual activity. Of the 31 patients who completed all FSFI questions, the median FSFI score was 24.0 and 21 (68%) had sexual dysfunction. Vaginal dryness was more common among patients receiving recurrent treatment (p = 0.09) while a "health condition" was a more common reason for sexual inactivity in the upfront setting (p = 0.07). CONCLUSION: Many patients receiving systemic therapy for gynecologic cancers are willing to discuss sexual function. Most patients reported sexual dysfunction and weren't currently sexually active. Understanding patients' sexual function concerns will allow providers to intervene.
引用
- Kulkarni A, Sun G, Manuppelli S, et al. Sexual health and function among patients receiving systemic therapy for primary gynecologic cancers. Gynecol Oncol. 2022. PMID: 35307202. doi:10.1016/j.ygyno.2022.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。